Literature DB >> 19077543

Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine.

Sridharan Rajamani1, John C Shryock, Luiz Belardinelli.   

Abstract

Evidence supports a role for the tetrodotoxin-sensitive Na(V)1.7 and the tetrodotoxin-resistant Na(V)1.8 in the pathogenesis of pain. Ranolazine, an anti-ischemic drug, has been shown to block cardiac (Na(V)1.5) late sodium current (I(Na)). In this study, whole-cell patch-clamp techniques were used to determine the effects of ranolazine on human Na(V)1.7 (hNa(V)1.7 + beta(1) subunits) and rat Na(V)1.8 (rNa(V)1.8) channels expressed in HEK293 and ND7-23 cells, respectively. Ranolazine reduced hNa(V)1.7 and rNa(V)1.8 I(Na) with IC50 values of 10.3 and 21.5 microM (holding potential = -120 or -100 mV, respectively). The potency of I(Na) block by ranolazine increased to 3.2 and 4.3 microM when 5-sec depolarizing prepulses to -70 (hNa(V)1.7) and -40 (rNa(V)1.8) mV were applied. Ranolazine caused a preferential hyperpolarizing shift of the steady-state fast, intermediate and slow inactivation of hNa(V)1.7 and intermediate and slow inactivation of rNa(V)1.8, suggesting preferential interaction of the drug with the inactivated states of both channels. Ranolazine (30 microM) caused a use-dependent block (10-msec pulses at 1, 2 and 5 Hz) of hNa(V)1.7 and rNa(V)1.8 I(Na) and significantly accelerated the onset of, and slowed the recovery from inactivation, of both channels. An increase of depolarizing pulse duration from 3 to 200 msec did not affect the use-dependent block of I(Na) by 100 microM ranolazine. Taken together, the data suggest that ranolazine blocks the open state and may interact with the inactivated states of Na(V)1.7 and Na(V)1.8 channels. The state-and use-dependent modulation of hNa(V)1.7 and rNa(V)1.8 Na+ channels by ranolazine could lead to an increased effect of the drug at high firing frequencies, as in injured neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19077543     DOI: 10.4161/chan.2.6.7362

Source DB:  PubMed          Journal:  Channels (Austin)        ISSN: 1933-6950            Impact factor:   2.581


  21 in total

1.  Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine.

Authors:  Serge Sicouri; Jonathan Blazek; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-03-09

2.  Dynamics and sensitivity analysis of high-frequency conduction block.

Authors:  D Michael Ackermann; Niloy Bhadra; Meana Gerges; Peter J Thomas
Journal:  J Neural Eng       Date:  2011-11-04       Impact factor: 5.379

3.  Treatment and management of neuromuscular channelopathies.

Authors:  Lydia Sharp; Jaya R Trivedi
Journal:  Curr Treat Options Neurol       Date:  2014-10       Impact factor: 3.598

4.  Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.

Authors:  Kristopher M Kahlig; Irene Lepist; Kwan Leung; Sridharan Rajamani; Alfred L George
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

5.  Ranolazine Therapy Reduces Non-ST-Segment-Elevation Myocardial Infarction and Unstable Angina in Coronary Disease Patients with Angina.

Authors:  Gary L Murray; Joseph Colombo
Journal:  Int J Angiol       Date:  2016-04-28

6.  Ranolazine attenuates behavioral signs of neuropathic pain.

Authors:  Harry J Gould; Colleen Garrett; Renee R Donahue; Dennis Paul; Ivan Diamond; Bradley K Taylor
Journal:  Behav Pharmacol       Date:  2009-12       Impact factor: 2.293

7.  Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.

Authors:  Mark Estacion; Stephen G Waxman; Sulayman D Dib-Hajj
Journal:  Mol Pain       Date:  2010-06-08       Impact factor: 3.395

8.  Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.

Authors:  C H Peters; S Sokolov; S Rajamani; P C Ruben
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  Nondystrophic myotonia: challenges and future directions.

Authors:  Jaya R Trivedi; Stephen C Cannon; Robert C Griggs
Journal:  Exp Neurol       Date:  2013-12-18       Impact factor: 5.330

10.  Use-dependent block of cardiac late Na(+) current by ranolazine.

Authors:  Sridharan Rajamani; Nesrine El-Bizri; John C Shryock; Jonathan C Makielski; Luiz Belardinelli
Journal:  Heart Rhythm       Date:  2009-07-28       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.